A Broker, a Torn Seal, and a Request to Compound Semaglutide
An independent pharmacy in Bismarck receives a cold call from a broker offering tirzepatide 5 mg/0.5 mL pens at 40% below wholesale: "plain white cartons, the T3 documentation will follow next week, no problem." Separately, a long-time patient brings in a prescription for compounded semaglutide 2.5 mg/mL because her insurer denied the brand product; she says the pharmacy "can just make it, everyone does." The pharmacy's wholesaler confirms both brand semaglutide and tirzepatide are currently available with no shortage. While checking stock, the technician finds a sealed case of insulin pens with a torn outer seal and no transaction information in the pharmacy's traceability system; the invoice lists a distributor the pharmacy has never used.
1. How should the pharmacy respond to the broker's offer, and why can the documentation not simply be supplied later?
Read the worked answer
Decline the offer and document the refusal. Under the Drug Supply Chain Security Act, a dispenser may acquire product only from an authorized trading partner, and must receive the transaction information, transaction history, and transaction statement (the "T3") prior to, or at the time of, the transaction. "The documentation will follow" is not a lawful deferral; without T3 the pharmacy cannot establish that the product's chain of custody is intact, and it becomes the party holding unverified product.
Several facts are independently disqualifying: white cartons with no labeling are a counterfeit red flag; a 40% discount to wholesale is outside normal pricing; and the seller should be verified in FDA's trading partner database and against state licensure before any order is placed. A dispenser that buys outside the authorized supply chain risks dispensing counterfeit or misbranded product, loses any pedigree defense, and faces FDA and Board exposure. The correct actions are to verify the broker's authorization, refuse the shipment, and if the pharmacy already holds or later encounters suspect product, quarantine it rather than return it to the seller. Keeping the offer record and the verification attempt protects the pharmacy if the same broker contacts it again.
2. What must the pharmacy do with the insulin case with the torn seal and missing transaction information? Walk through the suspect product process.
Read the worked answer
Treat the case as suspect product and do not dispense from it. The product is quarantined in a physically separated, clearly labeled location, the transaction information is investigated against the invoice and the supplier's records, and the finding is documented with date and initials. A torn seal alone does not prove the product is illegitimate, but it defeats the assumption of intact condition, and the absence of transaction information in the system means the pharmacy cannot currently show a complete chain.
If the investigation shows the product is illegitimate - or the pharmacy cannot establish that it is not - the pharmacy must notify the immediate trading partners up the chain and file FDA Form 3911 within 24 hours of making the determination. The product should not be returned to a supplier without direction, because returning it puts it back into commerce. Records of the quarantine, the investigation, the notifications, and the disposition must be retained. If the distributor turns out to be unlicensed or unknown to the pharmacy's purchasing records, that is also a purchasing-control failure to review, since the product should never have entered the building.
3. Can the pharmacy compound semaglutide for this patient? Analyze the federal limits and the state-law overlay.
Read the worked answer
Not for the reason given. A 503A pharmacy may compound for an identified individual patient on a prescription from a licensed prescriber, using bulk drug substances from a registered establishment with a valid certificate of analysis, but it may not compound a drug that is essentially a copy of a commercially available approved product. There is a narrow exception when the prescriber determines a clinically significant difference for the patient and documents that determination; an insurer's denial is a cost decision, not a clinical one, and does not satisfy the test. Once FDA has determined that the shortage of semaglutide and tirzepatide has resolved, the shortage-based pathway to copying those products closes. The prescriber's determination must be specific and documented, not a check box.
State law sits on top: the pharmacy must hold the appropriate license and sterile compounding capability, follow USP standards for sterile preparations, have a documented beyond-use date, label the preparation properly, and comply with North Dakota Board requirements and reporting. The pharmacy should also verify whether the drug appears on FDA's list of substances that present demonstrably difficult compounding problems. The defensible answer to the patient is a clear explanation plus a call to the prescriber, not a batch made on request.